Outcome of patients with AML in CR1 randomized to consolidation chemotherapy (cycle 3) or ASCT
| . | Cycle 3, no. (%) . | ASCT, no. (%) . |
|---|---|---|
| Total | 259 (100) | 258 (100) |
| Consolidation treatment | ||
| None | 6 (2) | 11 (4) |
| Chemotherapy | 240 (93) | 10 (4) |
| ASCT | 9 (3) | 236 (91) |
| Allogeneic SCT | 4 (2) | 1 (0) |
| RFS (actuarial 5 y) | P = .065 | |
| Median, mo | 11 | 14 |
| RFS | 69 (29) | 89 (38) |
| Relapse | 187 (70) | 156 (58) |
| Death in CR1 | 3 (1) | 13 (4) |
| OS (actuarial 5 y) | P = .86 | |
| Alive | 99 (41) | 101 (44) |
| Dead | 160 (59) | 157 (56) |
| Cause of death | ||
| AML | 119 (46) | 114 (44) |
| Pneumonitis | 8 (3) | 6 (2) |
| Other infections | 12 (5) | 8 (3) |
| Hemorrhage | 4 (2) | 4 (2) |
| GVHD | 4 (2) | 4 (2) |
| Secondary malignancy | 0 (0) | 1 (0) |
| Cardiac | 0 (0) | 2 (1) |
| Other | 13 (5) | 18 (7) |
| . | Cycle 3, no. (%) . | ASCT, no. (%) . |
|---|---|---|
| Total | 259 (100) | 258 (100) |
| Consolidation treatment | ||
| None | 6 (2) | 11 (4) |
| Chemotherapy | 240 (93) | 10 (4) |
| ASCT | 9 (3) | 236 (91) |
| Allogeneic SCT | 4 (2) | 1 (0) |
| RFS (actuarial 5 y) | P = .065 | |
| Median, mo | 11 | 14 |
| RFS | 69 (29) | 89 (38) |
| Relapse | 187 (70) | 156 (58) |
| Death in CR1 | 3 (1) | 13 (4) |
| OS (actuarial 5 y) | P = .86 | |
| Alive | 99 (41) | 101 (44) |
| Dead | 160 (59) | 157 (56) |
| Cause of death | ||
| AML | 119 (46) | 114 (44) |
| Pneumonitis | 8 (3) | 6 (2) |
| Other infections | 12 (5) | 8 (3) |
| Hemorrhage | 4 (2) | 4 (2) |
| GVHD | 4 (2) | 4 (2) |
| Secondary malignancy | 0 (0) | 1 (0) |
| Cardiac | 0 (0) | 2 (1) |
| Other | 13 (5) | 18 (7) |